Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jacobio Pharmaceuticals has inked an exclusive licensing agreement with Allist for two of its drugs, Glecirasib and JAB-3312, covering various regions in Greater China. The deal involves an upfront payment and R&D compensation totaling RMB200 million, with potential milestones that could add up to RMB700 million, plus tiered royalty payments for net sales. This strategic partnership is expected to boost the development and commercialization of the new treatments, with Jacobio retaining rights outside the agreed territories.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue